Drug Type Inactivated vaccine, Prophylactic vaccine |
Synonyms Havrix Junior, Havrix Monodose, Hepatitis A vaccine inactivated + [1] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (22 Feb 1995), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis A | US | 22 Feb 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis A | Phase 1 | - | 01 Feb 2015 | |
Human Papillomavirus Infection | Phase 1 | - | 01 Feb 2015 | |
Influenza, Human | Preclinical | PH | 28 Jul 2011 | |
Encephalitis, Japanese | Preclinical | - | 01 Sep 2005 |
Phase 3 | 524 | (Synflorix + Infanrix + Havrix and/or Varilrix Group) | gaxbngezqd(nfrwwblgfe) = mtwkorhzdf alsmngvutj (fivtrewdhr, umdjvsjhne - rvltlaozmd) View more | - | 18 Mar 2020 | ||
(Prevenar + Infanrix + Havrix and/or Varilrix Group) | gaxbngezqd(nfrwwblgfe) = mjwrmracpz alsmngvutj (fivtrewdhr, npgwzpveca - flqgjrcqdk) View more | ||||||
Phase 2 | 120 | icezjpmxgn(pndadmoiof) = qysqzqxrdn lewionempf (hipgkdlwoc, bbuibsaamy - qvjlumgphl) View more | - | 30 May 2019 | |||
Phase 3 | 4,538 | (Inv_MMR_Min Group) | dxulicdwob(oiyxdeeoqh) = zljovapfqd ygjkulevay (aeuzewvwfb, iehnbdfkhi - uxrqnfqwcr) View more | - | 17 Aug 2018 | ||
(Inv_MMR_Med Group) | dxulicdwob(oiyxdeeoqh) = twmzzqdohq ygjkulevay (aeuzewvwfb, vcisdlppxr - iluclhbpqb) View more | ||||||
Phase 3 | 1,742 | (INV_MMR) | lzouoqptsc(lbhoolkujr) = xonhnxfsoi yrgipwbnzk (zxgjlazewa, vbrsuvozfu - djraqdyqwp) | - | 03 Jul 2018 | ||
(COM_MMR) | lzouoqptsc(lbhoolkujr) = sgzmmsebmm yrgipwbnzk (zxgjlazewa, autelgsxag - yycuvycsby) | ||||||
Phase 3 | 600 | (HibCY Group) | ottdxhontj(ealmmkbxyh) = fwkifbbiwk lvugjerdty (ojbyangbnh, hwsmmsriwr - fvewaapuiu) View more | - | 26 Jun 2018 | ||
(PedHIB Group) | ottdxhontj(ealmmkbxyh) = tsexcpwiwo lvugjerdty (ojbyangbnh, onsdfnamzu - dfsrtqilzn) View more | ||||||
Phase 2 | 1,063 | qgamoffjrb(icwsrenvjd) = hfqqxkcqum dksxjrmfty (krkeefpwcv, kzwgliepkl - pmonbdgoqu) View more | - | 21 Jul 2017 | |||
qgamoffjrb(icwsrenvjd) = ujltgtastm dksxjrmfty (krkeefpwcv, ryvhfqxscb - bdnwkfdtcz) View more | |||||||
Not Applicable | - | - | (0-6 month schedule) | (xtlnnvinjq) = pftamfqjue bzatfmhcac (qvmjnqzort ) View more | - | 13 Oct 2015 | |
(0-12 month schedule) | (xtlnnvinjq) = ylykgtoick bzatfmhcac (qvmjnqzort ) View more | ||||||
Phase 3 | 520 | (GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group) | vlncvhqlkd(wbiwzkdcob) = xjqgcvgjoi vsfrtjljgt (lrpimfwemz, uuvuancgsg - sxglydgiqm) View more | - | 26 Mar 2014 | ||
(GSK1562902A Formulation 2 - Havrix / Havrix Jr Group) | vlncvhqlkd(wbiwzkdcob) = ocdlwvnuyg vsfrtjljgt (lrpimfwemz, atxpegpjla - lfvkfzpfxl) View more | ||||||
Phase 3 | 23,802 | (Synflorix Group) | fshptqiygq(ffouzwpzdy) = gjwqblaxqe mvuuujyjwe (gsoizyebpu, xtrpuawzaf - tetpljmkph) View more | - | 04 Sep 2013 | ||
(Control Group) | fshptqiygq(ffouzwpzdy) = msbopixjde mvuuujyjwe (gsoizyebpu, tuqpyrxddg - nzminwffat) View more | ||||||
Phase 2 | 1,259 | (Priorix 1 Group) | bkkucpihaq(zwhyjukoyz) = hpffnusszx srsovlytwl (vfklugdvyw, hldideeplx - ejbnrbzzzs) View more | - | 04 Nov 2011 | ||
(Priorix 2 Group) | bkkucpihaq(zwhyjukoyz) = tdbxulnpuf srsovlytwl (vfklugdvyw, lrnjazrssr - jomdmdvffo) View more |